Based on reported findings of the dysregulated metabolism in ALS patients and in vivo models of ALS, we tested the hypothesis that blocking or downregulation of lipid metabolism through CPT1 modulation affected disease progression in the SOD1 G93A mouse model of ALS. Here, CPT1A is linked to amyotrophic lateral sclerosis.